A monthly recap of the latest news about Alzheimer’s and dementia


Microphysiological systems: A promising new platform for Alzheimer’s drug development

One of the biggest and most persistent challenges in the quest for effective Alzheimer’s disease and related dementias therapies is finding better models for preclinical drug development. Read more here.


FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment | FDA

The U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease. Read more here.


Blood test for early Alzheimer’s detection

An NIH-funded research team led by Valerie Daggett at the University of Washington developed a method to detect toxic beta-amyloid oligomers in patients’ blood. Read more here.


Could a viral illness increase chances of developing Alzheimer’s or other neurodegenerative disease?

Some viral illnesses may increase a person’s chances of later developing Alzheimer’s disease or another neurodegenerative disorder. Read more here. 


Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer’s drug

In a somewhat surprising move, the US Food and Drug Administration (FDA) has declined to grant accelerated approval to Eli Lilly’s donanemab. Read more here.